NewswireToday - /newswire/ -
Irvine, CA, United States, 2011/06/09 - ChromaDex Corp. & the University of Mississippi announced the university has granted the natural products company exclusive worldwide patent rights to a potential new therapeutic use for pterostilbene (tero-STILL-bean) as an anxiolytic/anti-anxiety agent.
ChromaDex Corp. (OTCBB: CDXC) and the University of Mississippi today announced the university has granted the natural products company the exclusive worldwide patent rights to a potential new therapeutic use for pterostilbene (tero-STILL-bean) as an anxiolytic or anti-anxiety agent. ChromaDex’ pTeroPure® is an ultra-pure formulation of pterostilbene, a compound found in blueberries and demonstrated to have multiple health benefits.
ChromaDex continues its strategy of expanding its intellectual property supporting pterostilbene as the company builds its pTeroPure product portfolio and seeks partnerships to enter new markets. ChromaDex previously licensed two patents from the University of Mississippi that focus on the ability of pterostilbene to reduce blood lipoprotein levels and pterostilbene’s effect on oxidative stress and cognition. ChromaDex also holds rights to patents related to manufacturing claims.
“Adding the anxiolytic indication to our existing patent portfolio around pTeroPure allows us to capitalize on new product opportunities that we can pursue independently or with partners looking to differentiate their own products,” said ChromaDex President William Spengler. “ChromaDex will continue to seek partners such as the University of Mississippi so as to capture advancements in natural product research that will allow us to provide the marketplace with innovative proprietary ingredients.”
Research conducted by the University of Mississippi School of Pharmacy shows pterostilbene may have anxiolytic activities. The researchers determined pterostilbene activates the ERK signaling pathway in the hippocampus, an area of the brain speculated to play a role in anxiety. The effect of pterostilbene was investigated in a classic animal model of anxiety and found to be comparable in activity to the anti-anxiety drug diazepam used as the control drug in the model.
“We value our relationship with ChromaDex as a partner that has demonstrated a strong ability to commercialize products borne from our research to benefit people’s health and wellbeing,” said Walter Chambliss, Director Technology Management at the University of Mississippi.
The first human clinical research study on pTeroPure is being conducted at the University of Mississippi Medical Center to evaluate the compound in patients with lipid (cholesterol) disorders. Primary outcome measures include standard lipid laboratory markers. Secondary endpoints include blood pressure, markers of oxidative stress and safety.
For more information about pTeroPure, visit pteropure.com or call 949-600-9694.
ChromaDex (chromadex.com) is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company has an impressive pipeline of new ingredients, including its pTeroPure® pterostilbene for which it has worldwide, exclusive patent rights.
About the University of Mississippi
The University of Mississippi School of Pharmacy has earned international recognition for accomplishments in education; basic, translational and clinical research; and professional and community service. The school’s faculty members are heavily involved in teaching, research and patient care in a variety of settings, and it is home to the National Center for Natural Products Research, the nation’s only university research center devoted to improving human health and agricultural productivity through the discovery, development and commercialization of pharmaceuticals and agrochemicals derived from plants, marine organisms and other natural products.
ChromaDex Forward-Looking Statements
Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company’s Securities and Exchange Commission filings. The company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.
ChromaDex Investor Inquiries:
Liviakis Financial Communications, Inc.
John M. Liviakis, President
P: 415-389-4670 / E: John[.]Liviakis.com.
Jeremy Bartos, Product Development Manager
P: 949-600-9694 / E: jeremyb[.]pteropure.com.
University of Mississippi Contact:
Mitchel Diggs, Associate Director Media and Public Relations
P: 662-915-5639 / E: mdiggs[.]olemiss.edu.